Table 2

Detailed description of the diagnosis of the treated infections

Diagnosis, n (%)All,
N=366
Female, n=162Male, n=204
Respiratory tract infection121 (33)56 (35)65 (32)
 Pneumonia 82 (22)36 (22)46 (23)
  Viral pneumonia  9 (2) 7 (4.3) 2 (1)
  HAP  7 (2) 1 (0.6) 6 (2.9)
  CAP 66 (18)28 (17)38 (19)
 URTI  8 (2) 5 (3) 3 (1)
 COPD exacerbation  4 (1) 2 (1.2) 2 (1)
 Cough  4 (1) 2 (1.2) 2 (1)
 Bronchiectasis exacerbation  3 (1) 2 (1.2) 1 (0.5)
 Cystic fibrosis exacerbation  1 (0.3) 1 (0.5)
 LRTI  1 (0.3) 1 (0.6)
 Unspecified/chest infection 18 (5) 8 (5)10 (5)
Sepsis 55 (15)25 (15)30 (15)
 MDR Acinetobacter infection 13 (4) 7 (4) 6 (3)
Cellulitis 24 (7) 3 (2)21 (10)
Febrile neutropaenia 18 (5)11 (6.8) 7 (3.4)
VOC/SCD 15 (4) 7 (4.3) 8 (3.9)
ACS/SCD 16 (4) 8 (4.9) 8 (3.9)
Fever/fever of unknown origin 15 (4) 8 (4.9) 7 (3.4)
Meningitis  5 (1) 3 (1.9) 2 (1)
UTI 25 (7)15 (9.3)10 (4.9)
Skin infections  6 (2) 5 (3.1) 1 (0.5)
Gastrointestinal infection 21 (6) 6 (3.7)15 (7.4)
 Gastric ulcer perforation/bleeding  6 (2) 1 (0.6) 5 (2.5)
 Diarrhoea  4 (1) 1 (0.6) 3 (1.4)
 Ascites/ascetic tapping  4 (1) 2 (1.2) 2 (1)
 Pancreatitis  3 (1) 3 (1)
 Cholecystitis  2 (0.5) 1 (0.6) 1 (0.5)
Helicobacter pylori infection  1 (0.3) 1 (0.5)
 Peritonitis  1 (0.3) 1 (0.6)
Others  6 (2) 1 (0.6) 5 (2.5)
 Osteomyelitis  2 (0.5) 2 (1)
 Pleural effusion/pleural aspirate  3 (0.8) 1 (0.6) 2 (1)
 Fasciitis  1 (0.3) 1 (0.5)
No documented diagnosis 39 (11)14 (9)25 (12)
  • ACS, acute chest syndrome; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; HAP, hospital-acquired pneumonia; LRTI, lower respiratory tract infection; MDR, multidrug resistant; n, number of patients; SCD, sickle cell disease; URTI, upper respiratory tract infection; UTI, urinary tract infection; VOC, vaso-occlusive crisis.

  • Percentage might not add up to 100% due to rounding off.